An ASNC Information Statement: Radiopharmaceutical supply disruptions and the use of 99mTc-hydroxymethylene diphosphonate as an alternative to 99mTc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis
Resource Type
Information Statements, Practice Points
Year Published
2022
Related Resources
Cases
PET Case: The Mystery of Chest Pain with Patent Grafts
Case summary: This case illustrates the added value of myocardial blood flow…
PET Case: PET/CT for Complex Coronary Disease
Case summary: This case illustrates the role of multimodality imaging in a…
Cardiovascular Organizations Comment on OMB Proposed Regulation on Federal Financial Assistance
ASNC-ACC-ASE-SCAI-SCCT_Comments letter to OMB_07-13-2026
